Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03312556 · ClinicalTrials.gov registry record · NA

Treatment of Supine Hypertension in Autonomic Failure (CPAP)

A NA study of Autonomic Failure and Supine Hypertension, sponsored by Vanderbilt University Medical Center.

Recruiting
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT03312556 is a NA study of Autonomic Failure and Supine Hypertension that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 12 participants, below the 38-participant average among 11 other Autonomic Failure trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03312556, a NA study of Autonomic Failure and Supine Hypertension, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.

RECRUITING
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe and complicates the treatment of orthostatic hypotension. The purpose of this study is to assess whether continuous positive airway pressure (CPAP) decreases blood pressure in autonomic failure patients with supine hypertension.

Interventions

  • DRUG Placebo
  • DEVICE continuous positive airway pressure (CPAP)

Study Locations (1)

Tennessee

  • Autonomic Dysfunction Center/ Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2017-09-21
Est. Completion 2026-12-21
Phase NA

What the Registry Record Tells You About NCT03312556

The ClinicalTrials.gov registry entry for NCT03312556 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 38-participant average among 11 other Autonomic Failure trials with a reported enrollment target (68% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Autonomic Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03312556 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT03312556 about?

NCT03312556 is a clinical study titled "Treatment of Supine Hypertension in Autonomic Failure (CPAP)". Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe and complicates the treatment of orthostatic hypotension. The purpose of this study is to assess whether continuous positive airway pressure (CPAP) decrease...

What is the current status of trial NCT03312556?

This trial is currently recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2017-09-21. Estimated completion is 2026-12-21.

What conditions does trial NCT03312556 study?

This clinical trial studies the following conditions: Autonomic Failure, Supine Hypertension.

What interventions are being tested in trial NCT03312556?

The interventions under investigation include: Placebo (DRUG), continuous positive airway pressure (CPAP) (DEVICE).

Who is sponsoring clinical trial NCT03312556?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03312556 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autonomic Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.